Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer

Scandinavian Journal of Urology and Nephrology

Volumn 36, Issue 3, 2002, Pages 218-222

  Stavropoulos, N E ^a   Hastazeris, K ^a   Filiadis, I ^a   Mihailidis, I ^a   Ioachim, E ^b   Liamis, Z ^a   Kalomiris, P ^c  

^a G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c General Hospital of Sparta   (Greece)

Author keywords

Immunotherapy; Interferon gamma; Superficial bladder cancer

Indexed keywords

RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INTERFERON-GAMMA, RECOMBINANT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0036074729     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655902320131910     Document Type: Article

References (21)

1. Treatment of superficial bladder tumors: Achievements and needs
2. Treated history of noninvasive grade I transitional cell carcinoma
3. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma
4. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a European Organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone
5. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guirin for transitional-cell carcinoma of the bladder
6. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guirin in patients with superficial bladder carcinoma
7. Complications of bacillus Calmette-Guerin immunotherapy: Review of 2602 patients and comparison of chemotherapy complications
8. The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells
9. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy
10. Antiproliferative activity of interferon gamma in superficial bladder cancer
11. Local immune response after intravesical interferon gamma in superficial bladder cancer
12. Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer
13. Biological response modifiers for the treatment of superficial bladder tumors
14. Acute effects of single doses of recombinant interferon gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer
15. Efficacy of escalating doses of intravesical interferon a-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma
16. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder
17. Factors affecting recurrence and progression in superficial bladder tumors
18. BCG versus interferon A for prevention of recurrence of superficial bladder cancer: A prospective randomized study
19. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder
20. Superficial bladder cancer: The role of interferon-α
21. Experimental and clinical evidence of enhancement of BCG efficacy by adding interferon-alpha